• Publications
  • Influence
Remission in schizophrenia: proposed criteria and rationale for consensus.
TLDR
The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness. Expand
Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria
TLDR
An overview of decisions from the first MATRICS consensus conference is presented, which constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia. Expand
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
TLDR
Aripiprazole is the first non-D2 receptor antagonist with clear antipsychotic effects and represents a novel treatment development for psychotic disorders. Expand
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
TLDR
The large between-group differences on negative symptoms, hostility/excitement, and anxiety/depression suggest that risperidone and other serotonin/dopamine antagonists have qualitatively different effects from those of conventional antipsychotic agents. Expand
Physical health monitoring of patients with schizophrenia.
TLDR
A consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings, including regular monitoring of body mass index, plasma glucose level, lipid profiles, and signs of prolactin elevation or sexual dysfunction are discussed. Expand
The brief negative symptom scale: psychometric properties.
TLDR
The Brief Negative Symptom Scale (BNSS) is a 13-item instrument designed for clinical trials and other studies that measures these 5 domains and the interrater, test-retest, and internal consistency of the instrument were strong. Expand
Risperidone in the treatment of schizophrenia.
TLDR
The results indicate that the optimal daily dose of risperidone for most schizophrenic patients in this study was 6 mg; this dose was as effective as 16 mg, and the incidence of extrapyramidal symptoms in patients receiving 6 mg of ris peridone was no higher than that in Patients receiving placebo. Expand
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
TLDR
Aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation and may offer benefits in schizophrenia treatment. Expand
Pharmacokinetics and tissue distribution of olanzapine in rats
TLDR
The data indicated that olanzapine is rapidly absorbed and widely distributed in the tissues of rats after oral and i.p. administration, and the plasma concentration appears to predict the simultaneous concentration in brain and other tissues. Expand
Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study
TLDR
Paliperidone ER, particularly the 6-mg dose, was effective and well tolerated, and provides a valuable new treatment option for schizophrenia. Expand
...
1
2
3
4
5
...